Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5406478 | 1.00 | HTR2C (0.38) | HTR2CPRCPCHRNB2CHRNA4CHRNA3 | |
| SCHEMBL19584360 | 0.89 | PRCP (0.43) | HTR2CPRCPKDM4ETLR2HTR2B | |
| Tert-Butyl Formate SCHEMBL28282934 | 0.80 | PRCP (0.35) | HTR2CPRCPKDM4ETLR2HTR2B | |
| Trifluoroacetic Acid SCHEMBL5403204 | 0.78 | NOS2 (0.38) | HTR2CPRCP | |
| Trifluoroacetic Acid SCHEMBL5403202 | 0.78 | NOS2 (0.38) | HTR2CPRCP | |
| Trifluoroacetic Acid SCHEMBL29935426 | 0.77 | PRCP (0.38) | HTR2CPRCP | |
| Trifluoroacetic Acid SCHEMBL3332141 | 0.75 | PRCP (0.56) | HTR2CPRCPKDM4EHTR2ATLR2 | |
| Proline SCHEMBL6986151 | 0.74 | MEN1 (0.42) | HTR2CPRCP | |
| Proline SCHEMBL10781489 | 0.74 | MEN1 (0.42) | HTR2CPRCP | |
| Trifluoroacetic Acid SCHEMBL28882423 | 0.74 | CYP3A4 (0.41) | HTR2CPRCPCHRNB2CHRNA4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | ORION CORPORATION (FI) | 2006-10-12 | — | — | US | disclosed |
| EP-1581489-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2005-10-05 | — | — | EP | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| WO-2004060862-A2 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY | ORION CORPORATION (FI) | 2004-07-22 | — | — | WO | disclosed |
| US-4626545-A | Amino acid derivatives as enzyme inhibitors | MERCK & CO., INC. (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229254-A1 | Compounds having prolyl oligopeptidase inhibitory activity | PREP, DNPEP, IDE | HTR2C 4604/4885PRCP 18/4885CHRNB2 3323/4885 |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | HTR2C 4238/4885PRCP 43/4885CHRNB2 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.